Start of final bull run ahead of 9th November FDA announcement of Heplisav approval $25-$30 price projection
Equivalent long term investability of ETH but at a 1/30th of the current price. Expecting that Bitcoin will dump (temporarily) in the near future. The relative BTC value of ETC is likely to surge. In addition ETC does not follow the trend of ETH or BTC and therefore is more likely to see a surge of investment on a BTC crash
Start of a bull run on Heron Therapeutics. Initial catalyst: PDUFA review of Cinvanti 11 November 2017 Secondary catalyst: Fast track designation for HTX-011
Start of final bull run ahead of 9th November FDA announcement of Heplisav . $28 price projection. Final buy opportunity at $20
Lowest price buy in $20.7 ahead of the upcoming PDUFA decision. Projected price target $30